These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 33986332)

  • 41. hiPSC-CM Monolayer Maturation State Determines Drug Responsiveness in High Throughput Pro-Arrhythmia Screen.
    da Rocha AM; Campbell K; Mironov S; Jiang J; Mundada L; Guerrero-Serna G; Jalife J; Herron TJ
    Sci Rep; 2017 Oct; 7(1):13834. PubMed ID: 29061979
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An in silico-in vitro pipeline for drug cardiotoxicity screening identifies ionic pro-arrhythmia mechanisms.
    Clark AP; Wei S; Kalola D; Krogh-Madsen T; Christini DJ
    Br J Pharmacol; 2022 Oct; 179(20):4829-4843. PubMed ID: 35781252
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model.
    Guo L; Coyle L; Abrams RM; Kemper R; Chiao ET; Kolaja KL
    Toxicol Sci; 2013 Dec; 136(2):581-94. PubMed ID: 24052561
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Overexpression of KCNJ2 in induced pluripotent stem cell-derived cardiomyocytes for the assessment of QT-prolonging drugs.
    Li M; Kanda Y; Ashihara T; Sasano T; Nakai Y; Kodama M; Hayashi E; Sekino Y; Furukawa T; Kurokawa J
    J Pharmacol Sci; 2017 Jun; 134(2):75-85. PubMed ID: 28615142
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drug response analysis for scaffold-free cardiac constructs fabricated using bio-3D printer.
    Arai K; Murata D; Takao S; Nakamura A; Itoh M; Kitsuka T; Nakayama K
    Sci Rep; 2020 Jun; 10(1):8972. PubMed ID: 32487993
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessment of beating parameters in human induced pluripotent stem cells enables quantitative in vitro screening for cardiotoxicity.
    Sirenko O; Cromwell EF; Crittenden C; Wignall JA; Wright FA; Rusyn I
    Toxicol Appl Pharmacol; 2013 Dec; 273(3):500-7. PubMed ID: 24095675
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes.
    Lee S; Lee HA; Choi SW; Kim SJ; Kim KS
    Toxicol Appl Pharmacol; 2016 Apr; 296():42-53. PubMed ID: 26821276
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cardiotoxicity Hazard and Risk Characterization of ToxCast Chemicals Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes from Multiple Donors.
    Burnett SD; Blanchette AD; Chiu WA; Rusyn I
    Chem Res Toxicol; 2021 Sep; 34(9):2110-2124. PubMed ID: 34448577
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Finding the rhythm of sudden cardiac death: new opportunities using induced pluripotent stem cell-derived cardiomyocytes.
    Sallam K; Li Y; Sager PT; Houser SR; Wu JC
    Circ Res; 2015 Jun; 116(12):1989-2004. PubMed ID: 26044252
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of In Vitro Drug-Induced Cardiotoxicity Assay by Using Three-Dimensional Cardiac Tissues Derived from Human Induced Pluripotent Stem Cells.
    Takeda M; Miyagawa S; Fukushima S; Saito A; Ito E; Harada A; Matsuura R; Iseoka H; Sougawa N; Mochizuki-Oda N; Matsusaki M; Akashi M; Sawa Y
    Tissue Eng Part C Methods; 2018 Jan; 24(1):56-67. PubMed ID: 28967302
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Modeling Short QT Syndrome Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    El-Battrawy I; Lan H; Cyganek L; Zhao Z; Li X; Buljubasic F; Lang S; Yücel G; Sattler K; Zimmermann WH; Utikal J; Wieland T; Ravens U; Borggrefe M; Zhou XB; Akin I
    J Am Heart Assoc; 2018 Mar; 7(7):. PubMed ID: 29574456
    [TBL] [Abstract][Full Text] [Related]  

  • 52. GS-967 and Eleclazine Block Sodium Channels in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Potet F; Egecioglu DE; Burridge PW; George AL
    Mol Pharmacol; 2020 Nov; 98(5):540-547. PubMed ID: 32938719
    [TBL] [Abstract][Full Text] [Related]  

  • 53. From the Cover: High-Throughput Imaging of Cardiac Microtissues for the Assessment of Cardiac Contraction during Drug Discovery.
    Pointon A; Pilling J; Dorval T; Wang Y; Archer C; Pollard C
    Toxicol Sci; 2017 Feb; 155(2):444-457. PubMed ID: 28069985
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Human Induced Pluripotent Stem Cell-Derived Engineered Heart Tissue as a Sensitive Test System for QT Prolongation and Arrhythmic Triggers.
    Lemoine MD; Krause T; Koivumäki JT; Prondzynski M; Schulze ML; Girdauskas E; Willems S; Hansen A; Eschenhagen T; Christ T
    Circ Arrhythm Electrophysiol; 2018 Jul; 11(7):e006035. PubMed ID: 29925535
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Engineering a functional three-dimensional human cardiac tissue model for drug toxicity screening.
    Lu HF; Leong MF; Lim TC; Chua YP; Lim JK; Du C; Wan ACA
    Biofabrication; 2017 May; 9(2):025011. PubMed ID: 28393762
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Computational prediction of drug response in short QT syndrome type 1 based on measurements of compound effect in stem cell-derived cardiomyocytes.
    Jæger KH; Wall S; Tveito A
    PLoS Comput Biol; 2021 Feb; 17(2):e1008089. PubMed ID: 33591962
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assessment of Cardiotoxicity With Stem Cell-based Strategies.
    Stella Stoter AM; Hirt MN; Stenzig J; Weinberger F
    Clin Ther; 2020 Oct; 42(10):1892-1910. PubMed ID: 32938533
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Abnormalities in sodium current and calcium homoeostasis as drivers of arrhythmogenesis in hypertrophic cardiomyopathy.
    Coppini R; Santini L; Olivotto I; Ackerman MJ; Cerbai E
    Cardiovasc Res; 2020 Jul; 116(9):1585-1599. PubMed ID: 32365196
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Activated Cardiac Fibroblasts Control Contraction of Human Fibrotic Cardiac Microtissues by a β-Adrenoreceptor-Dependent Mechanism.
    Błyszczuk P; Zuppinger C; Costa A; Nurzynska D; Di Meglio FD; Stellato M; Agarkova I; Smith GL; Distler O; Kania G
    Cells; 2020 May; 9(5):. PubMed ID: 32443848
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro to in vivo extrapolation from 3D hiPSC-derived cardiac microtissues and physiologically based pharmacokinetic modeling to inform next-generation arrhythmia risk assessment.
    Daley MC; Moreau M; Bronk P; Fisher J; Kofron CM; Mende U; McMullen P; Choi BR; Coulombe K
    Toxicol Sci; 2024 Sep; 201(1):145-157. PubMed ID: 38897660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.